We are a Swiss law firm, dedicated to providing legal solutions to business, tax and regulatory matters.
Life Sciences, Pharma, Biotech
Litigation and Arbitration
Find a lawyer
Our knowledge, expertise & publications
Deals & Cases
17 December 2021
Anaveon AG ("Anaveon"), a Swiss clinical-stage immuno-oncology company, has agreed to a CHF 110m Series B financing led by incoming investor Forbion, corner-stoned by founding investor Syncona, also joined by existing investor Novartis Venture Fund, as well as new investors, Cowen Healthcare Investments (a division of Cowen Investment Management), Pfizer Ventures and Pontifax. In connection with the Series B financing, Jasper Bos (Forbion), Tim Anderson (Cowen) and Denis Patrick (Pfizer Ventures) will join the Anaveon Board at closing, which is expected before year end. Proceeds from this financing will enable the Company to pursue multiple parallel Phase II programs in order to explore the full therapeutic potential of ANV419, a powerful and selective interleukin-2 (IL-2) agonist in patients with solid tumors, and to grow the pipeline into new indications.
VISCHER advises Anaveon on all legal and tax issues related to the transaction. The VISCHER team includes Christian Wyss (Partner, Corporate/M&A), Nadia Tarolli (Partner, Tax), Sebastian Flückiger (Senior Associate, Corporate/M&A), Luzius Zumstein (Senior Associate, Corporate/M&A), Delia Fehr-Bosshard (Managing Associate, Intellectual Property) and Christoph Enz (Associate, Corporate/M&A).
Categories: Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Startup Desk
Attorney at Law
Attorney at Law, Swiss Certified Tax Expert (2008)
Chambers and Partners published their Europe Guide 2022. We are pleased to announce that our firm...
On March 16, 2022, the online Swiss Chinese Life Sciences Forum is going to take place for the fifth...
Am 27. Oktober findet der Due Diligence Workshop in Zusammenarbeit mit SLTA Student Chapter Basel an...
Opt-in for our regular updates, news, views, insights and more.